Nicole Fawcett

Maria Castro, Ph.D, of Michigan Medicine, received a prestigious $4.5M NIH grant that will help advance the understanding about deadly tumors and provide a path for developing new treatments.

The University of Michigan Rogel Cancer Center has named Christopher J. Liekweg, M.B.A., CMPE, associate director for administration and chief department administrator. Liekweg is a senior administrator at VCU Health, the academic medical center of Virginia

The University of Michigan Rogel Cancer has named two new deputy directors and a new associate director to provide strategic leadership in cancer care, research and training: Michael Deininger, M.D., Ph.D.; Lesly Dossett, M.D., M.P.H.; and Samuel Kaffenberger, M.D.

Rogel Cancer Center researcher Steven J. Katz, M.D., M.P.H., on how genetic testing results impact both the cancer patient and their family.

Why smokers have a higher chance of developing pancreatic cancer and why they tend to have worse outcomes than nonsmokers, according to a new study by University of Michigan Health Rogel Cancer Center.

A new study from University of Michigan Rogel Cancer Center researchers identifies a cellular signature that explains why about one-third of prostate cancers respond especially poorly to treatment. 

A study explains the genetic underpinnings of a rare and aggressive form of ovarian cancer – and offers a potential pathway for new treatments.

As recommendations suggest extending hormone-based breast cancer treatment to 10 years for some patients, a recent study sheds light on whether patients are opting for it.

Researchers from the University of Michigan received a $6 million center grant from the National Institutes of Health to establish the new National Center for Biomedical Imaging and Bioengineering (NCBIB).

University of Michigan Health Rogel Cancer Center scientists identified a gene that plays a key role in prostate cancer cells that have transitioned to a more aggressive, treatment-resistant form. The gene can be indirectly targeted with an existing class of drugs, suggesting a potential treatment strategy for patients with aggressive subtypes of prostate cancer.

The Forbes Institute fosters cross-disciplinary collaboration, encouraging partnerships among faculty from various disciplines across the University of Michigan campus. Learn more about their research into tumor dormancy.

Research by the University of Michigan Health Rogel Cancer Center finds that patients with three of these variants face no extra risk of dying from their cancer.

A specialist outlines some recent advances that have him excited for the future of multiple myeloma treatment.

Andrea Franson, M.D., M.S., received an $800,000 “A” Award grant from Alex’s Lemonade Stand Foundation for Childhood Cancer to translate an approach developed at Rogel Cancer Center into a phase 1 clinical trial for children with high-grade glioma.

Andrea Franson, M.D., M.S., received an $800,000 “A” Award grant from Alex’s Lemonade Stand Foundation for Childhood Cancer to translate an approach developed at Rogel Cancer Center into a phase 1 clinical trial for children with high-grade glioma.